Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for VCAR33 (ALLO) in Acute myeloid leukemia. The expected timing is based on the latest available company guidance and may change.
VBP301 trial. IND cleared by FDA. Presentation at ASH 2023. 01/17/24- Dosed first patient. 3/20/25- Dosing ongoing w/ clinical data update in H1 2025. 5/8/25- Discontinued all clinical and manufacturing operations, including ongoing clinical trials. 08/11/26:- UPSTREAM MG enrollment ongoing; topline data still anticipated in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.